FH-MCVA2TCR

· Fred Hutchinson Cancer Center

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for FH-MCVA2TCR, covering 2025-03-06 to 2025-03-06. Get the full timeline:

Most recent: Clinical Trial Update: Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer [Phase 1, Phase 2]

See pricing